Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Megestrol acetate as a biomodulator

A Y Chang1

  • 1Upstate NY Cancer Research and Education Foundation, Rochester 14623, USA.

Seminars in Oncology
|June 13, 1998
PubMed
Summary
This summary is machine-generated.

Megestrol acetate, a progesterone analog, may improve quality of life and reverse multidrug resistance in cancer patients. Further research is needed to explore its potential in enhancing chemotherapy and patient well-being.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of dermatological diagnoses among hospitalized patients experiencing homelessness.

Clinical and experimental dermatology·2021
Same author

Identifying gaps in global health dermatology: a survey of GLODERM members.

The British journal of dermatology·2021
Same author

The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies.

The British journal of dermatology·2020
Same author

Response to 'Providing dermatological care in resource-limited settings: barriers and potential solutions' - reply from authors.

The British journal of dermatology·2017
Same author

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.

Leukemia·2017
Same author

Providing dermatological care in resource-limited settings: barriers and potential solutions.

The British journal of dermatology·2017

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Megestrol acetate is a synthetic progesterone analog with known effects on weight and quality of life in various patient populations.
  • Its mechanism for improving quality of life in cancer and acquired immunodeficiency syndrome (AIDS) patients is not fully understood.
  • Emerging research suggests megestrol acetate may counteract multidrug resistance (MDR) in cancer cell lines.

Purpose of the Study:

  • To investigate the potential of megestrol acetate in reversing multidrug resistance (MDR) in cancer.
  • To evaluate its capacity to enhance the efficacy of chemotherapeutic agents like doxorubicin and vincristine.
  • To explore its role in improving the quality of life for cancer patients.

Main Methods:

  • In vitro studies examining the interaction of megestrol acetate with p-glycoprotein.

Related Experiment Videos

  • Assessment of megestrol acetate's effect on cancer cell lines exhibiting multidrug resistance.
  • Evaluation of its impact on the cytotoxicity of doxorubicin and vincristine in both MDR and non-MDR cell lines.

    • Main Results:

    • Megestrol acetate demonstrated partial reversal of multidrug resistance to doxorubicin and/or vincristine in cancer cell lines.
    • The drug's unique binding to p-glycoprotein is implicated in this observed biological activity.
    • In vitro, megestrol acetate enhanced the cytotoxic effects of doxorubicin and vincristine in some cell lines lacking MDR.

    Conclusions:

    • Megestrol acetate shows promise in overcoming chemotherapy resistance.
    • Its potential to improve quality of life and enhance chemotherapy efficacy warrants further investigation.
    • Additional preclinical and clinical studies are recommended to fully elucidate the therapeutic potential of megestrol acetate in oncology.